Dr. Berardo Francesca
Orthoptist, Ophthalmic Assistant
Research unit: RU Glaucoma
Simple Operating Unit: Simple Operating Unit Glaucoma and Hospital-Territory Integration
Specialization: Orthoptist, Ophthalmic Assistant
Professional register: Registered with the Professional Order of Health Technicians in Medical Radiology and Technical Health Professions in Rehabilitation and Prevention of Rome and Province, Registration No. 65, dated November 23, 2018.
Practices at IRCCS Fondazione G.B. Bietti, in the facilities of Via Livenza, 3 and Via di Santo Stefano Rotondo, 6, at the Presidio Ospedaliero Britannico, Rome.
Scientific Publications: PubMed
LinkedIn Profile: Francesca Berardo
- 2008: Graduated with honors (cum laude) with a Degree in Orthoptics and Ophthalmic Assistance from the Catholic University of the Sacred Heart “A. Gemelli,” Rome (Larino Campus).
- 2009: Completed the Advanced Course (Corso di Perfezionamento) in “Visual Rehabilitation” at the University of Florence, Faculty of Medicine and Surgery – Department of Oto-Neuro-Ophthalmological Surgical Sciences.
2010–2012: Fellow at the Glaucoma Research Line
2013–2015: Contract Researcher at the Glaucoma Research Line
2016: Permanent Employee
- Technical support activity for scientific research of the Glaucoma Unit: Ophthalmic assistance in instrumental diagnostics for glaucoma, spanning both outpatient services and research activities.
- Efficacy and safety assessment of T4030 eye drops versus Ganfort® UD in ocular hypertensive or glaucomatous patients (THEA 2).
- International, multicenter, non-pharmacological interventional study for the evaluation of new endpoints for glaucoma and identification of the optimal patient population for neuroprotection studies (CBASICHR0031 – NOVARTIS).
- Evaluation of spatial summation in the central 10 degrees of the visual field: development of a neural model for structure-function analysis.
- 24-hour efficacy and tolerability of the preservative-free fixed combination of tafluprost–timolol in glaucomatous or ocular hypertensive patients already treated with latanoprost preserved with BAK. A 3-month prospective, open-label study (HERO).
- Phase III, multinational, multicenter, investigator-masked, randomized, active-controlled study to compare the efficacy and safety of DE-130A versus Xalatan® in patients with open-angle glaucoma or ocular hypertension over 3 months, followed by a 12-month open-label follow-up with DE-130A treatment. (CATIOPROST – 0130A01SA).
- Evaluation of the efficacy and safety of T4032 (preservative-free bimatoprost 0.01%) versus Lumigan® 0.01% in patients with ocular hypertension or glaucoma (THEA 1).
- A prospective, double-masked, randomized, multicenter, active-controlled, parallel-group, 6-month study assessing the safety and ocular hypotensive efficacy of PG324 Ophthalmic Solution compared to GANFORT® (bimatoprost 0.03%/timolol 0.5%) Ophthalmic Solution in subjects with elevated intraocular pressure (MERCURY 3).
- Preservative-free fixed-dose combination of tafluprost 0.0015% / timolol 0.5% in patients with open-angle glaucoma or ocular hypertension: Clinical effectiveness, tolerability and safety in a real world setting.
- Efficacy of an ophthalmic solution based on taurine and hyaluronic acid in glaucomatous and ocular hypertensive patients undergoing chronic treatment with ocular hypotensive drugs.
- Safety and Efficacy with Twice Daily Brinzolamide 1% / Brimonidine 0.2% (SIMBRINZA) as an Adjunctive Therapy to Travoprost 0.004% / Timolol 0.5% (DUOTRAV).
- Intraocular pressure and tolerability study of preserved Bimatoprost 0.1% (BMD) or Tafluprost Unit Dose Preservative Free 15microgram/ml (TUDPF) (Saflutan), in patients with Ocular hypertension or glaucoma suitable for prostaglandin therapy: A Randomized, single-masked, 3-month cross-over, Investigator-led, European multicenter Trial, II (SPORT II).
- Clinical performance of Compass in the diagnosis of Glaucoma.
- A phase IV study on the changes in ocular signs and symptoms in patients with ocular hypertension or open-angle glaucoma switched from Ganfort eye drops to Taptiqom eye drops (SANTEN II).
- Evaluation of BDNF and NGF levels in the plasma and tears of patients with glaucoma. NTs and glaucoma.
- Side effects of preservatives: clinical, cytological, and instrumental evaluation of the ocular surface.
- Intraocular pressure and tolerability study of Preservative Free Bimatoprost 0.03% Unit Dose (BUDPF) or Preservative Free Latanoprost 0.005% Unit Dose (LUDPF) (Monoprost®) in patients with Ocular hypertension or glaucoma: A Randomized, single-masked, 3-month cross-over, Investigator-led, European multicenter Trial (SPORT).
- Comparison of the intraocular pressure-lowering effect of the fixed bimatoprost-timolol combination versus fixed carbonic anhydrase inhibitor-timolol combinations in patients with glaucoma or ocular hypertension uncontrolled by monotherapy: a retrospective study.
- Efficacy of an ophthalmic solution based on cyanocobalamin, taurine, and hyaluronic acid in patients undergoing therapy with ocular hypotensive drugs.
- Evaluating the intraocular pressure-lowering efficacy of Miotrab administered three times daily.
- Lumigan 0.1® in daily outpatient activity: a retrospective study.
- Learning effect of HEP (Heidelberg Edge Perimeter) perimetry in patients with ocular hypertension.
- Influence of pupillary dilation on measurements of the Retinal Nerve Fiber Layer (RNFL), Optic Nerve Head (ONH), and Ganglion Cell Complex (GCC) using Spectral Domain Optical Coherence Tomography (OCT) (RTVue -100).
- Prospective longitudinal study for the evaluation of ocular surface disease development. Comparison between Treatment-Naive patients (who have not received specific treatments) with ocular hypertension or glaucoma versus patients without elevated ocular pressure. (SAHARA).
- Evaluation of the therapeutic equivalence of Travoprost PR and Travatan: a randomized, double-blind clinical study in patients with glaucoma or ocular hypertension.
- A 2-year, multicenter, double-blind, randomized, parallel-group study on the safety of LUMIGAN® 0.1 mg/ml versus LUMIGAN® 0.3 mg/ml in patients with glaucoma or ocular hypertension.
- A phase III, randomized, double-masked 6-month clinical study to compare the efficacy and safety of the preservative-free fixed-dose combination of tafluprost 0.0015% and timolol 0.5% eye drops to those of tafluprost 0.0015% and timolol 0.5% eye drops given as individual monotherapies in patients with open-angle glaucoma or ocular hypertension.
- Comparison of the effects of Bimatoprost 0.01% and Timolol 0.5% on circadian intraocular pressure.
- Multi-Center Study Assessing Efficacy and Tolerability of TRAVATAN solution without BAK, containing Polyquad Preservative (0.004% travoprost) in Patients Previously on latanoprost 0.005% or bimatoprost 0.01% ophthalmic solution Monotherapy.
- Evaluation of patients with retinal nerve fiber layer alteration using SITA Standard perimetry and SITA SWAP perimetry.
- A comparison between the Moorfields MDT and established perimeters to discriminate between normal and glaucomatous eyes.
